Irinotecan Study For Cervical Cancer
The purpose of the study is to evaluate the efficacy and safety of Irinotecan plus cisplatin as first-line chemotherapy for advanced or recurrent cervical cancer
Uterine Cervical Neoplasms
DRUG: Irinotecan
Response to Treatment Based on Response Evaluation Criteria in Solid Tumors (RECIST) Criteria (Evaluable Population), Tumor response according to RECIST., At baseline and every 8 weeks through end of treatment (21-28 days after last administration of study treatment)|Response to Treatment Based on RECIST Criteria (Intent-to-Treat [ITT] Population), Tumor response according to RECIST., At baseline and every 8 weeks through end of treatment (21-28 days after last administration of study treatment)
Overall Survival (OS) and Time to Tumor Progression (TTP) (Evaluable Population), TTP is date of first infusion to first date of documented progression or date of death due to progressive disease or date of further anti-tumor therapy, whichever occurs first. OS is time from date of first infusion to date of death due to any cause or last date patient is known to be alive at date of data cutoff for final analysis., Tumor response measurements were made at baseline, according to RECIST criteria. After end of treatment, subject was followed-up every 12 weeks plus or minus 2 weeks.|Overall Survival (OS) and Time to Tumor Progression (ITT Population), TTP is date of first infusion to first date of documented progression or date of death due to progressive disease or date of further anti-tumor therapy, whichever occurs first. OS is time from date of first infusion to date of death due to any cause or last date patient is known to be alive at date of data cutoff for final analysis., Tumor response measurements were made at baseline, according to RECIST criteria. After end of treatment, subject was followed-up every 12 weeks plus or minus 2 weeks.
The purpose of the study is to evaluate the efficacy and safety of Irinotecan plus cisplatin as first-line chemotherapy for advanced or recurrent cervical cancer